Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that the company will be participating in the Rodman & Renshaw 13th Annual Global Investment Conference being held at the Waldorf-Astoria Hotel in New York City from September 11th – 13th. Edward J. Quilty, Chairman and CEO, will deliver the Company’s corporate presentation on Monday, September 12th, at 10:00 a.m. (Eastern Time).

The presentation will be webcast live at http://www.wsw.com/webcast/rrshq20/dsci and on the Investor Relations section of the Company’s website at www.dermasciences.com, where it will also be archived for 90 days.

Derma Sciences is a medical technology company focused on the wound care marketplace, addressing; traditional dressings, advanced wound care dressings, and pharmaceutical wound care products. Its MEDIHONEY product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB for better management of wound exudate, and BIOGUARD for infection prevention. Derma Sciences has successfully completed a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction.

For more information please visit www.dermasciences.com.

Copyright Business Wire 2010